AI assistant
HAEMONETICS CORP — Director's Dealing 2024
May 21, 2024
31565_dirs_2024-05-21_e4f93627-415c-4660-9999-b80b1f544265.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-05-17
Reporting Person: Llorens Josep (EVP, Global Manufacturing)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-17 | Common Stock | S | 822 | $94.82 | Disposed | 16350 | Direct |
| 2024-05-17 | Common Stock | F | 320 | $95.73 | Disposed | 16030 | Direct |
| 2024-05-17 | Common Stock | A | 6267 | — | Acquired | 22297 | Direct |
| 2024-05-20 | Common Stock | S | 987 | $95.08 | Disposed | 21310 | Direct |
Footnotes
F1: Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023).
F2: This number includes unvested restricted stock units ("RSUs") previously reported.
F3: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.
F4: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F5: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.